Zum Hauptinhalt springen
| Hans-Günter Meyer-Thompson | International

Neurocognitive, psychiatric, and substance use characteristics in a diverse sample of persons with OUD who are starting methadone or buprenorphine/naloxone in opioid treatment programs. 

Neurocognitive, psychiatric, and substance use characteristics in a diverse sample of persons with OUD who are starting methadone or buprenorphine/naloxone in opioid treatment programs. 

Scott TM, Arnsten J, Olsen JP, Arias F, Cunningham CO, Rivera Mindt M. 

Neurocognitive Addict Sci Clin Pract. 2021 Oct 24;16(1):64. doi: 10.1186/s13722-021-00272-4. PMID: 34689841; PMCID: PMC8543954.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8543954/